Cognitive-psychophysiological Treatment for Tics in Young People With Tourette's Syndrome With or Without Biofeedback (CoBRa)
Can the Cognitive-Psychophysiological Treatment of Tics be Optimized Through Biofeedback in Adolescents and Emerging Adults With Tourette Syndrome? - A Randomized Clinical Trial
The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults.
Hypotheses:
- The CoPs+Biofeedback treatment will improve the severity of tics (YGTSS) and the Clinical Global Impression, surpassing the clinical significance threshold of CoPs treatment alone.
- We expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics.
Researchers will compare if the biofeedback treatment will improve the severity of tics.
- In the pre-test, participants will undergo two interviews, each lasting 3 hours. These interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. A general assessment of intelligence and executive functions will also be conducted.
- They will next attend 10 to 12 therapy sessions, with or without biofeedback. (The biofeedback component is explained in more detail in the ''Study Design'' section).
- The post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. The evaluation will be done using the same battery of tests as during the pre-test interview.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Julie Leclerc, Psychology
- Phone Number: 5267 1-514-987-3000
- Email: leclerc.julie@uqam.ca
Study Contact Backup
- Name: Audrey-Ann Lachance
- Phone Number: 2381 1-514-323-7260
- Email: audrey-ann.lachance.cnmtl@ssss.gouv.qc.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H1E 1A4
- Recruiting
- Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal, Hôpital Rivières-des-Prairies
-
Contact:
- Julie Leclerc
- Phone Number: 2190 514-323-7260
- Email: leclerc.julie@uqam.ca
-
Contact:
- Audrey-Ann Lachance
- Phone Number: 2381 5143237260
- Email: audrey-ann.lachance.cnmtl@ssss.gouv.qc.ca
-
Principal Investigator:
- Julie Leclerc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a diagnosis of TS or to experience bothersome tics;
- Be aged 14 to 21 years inclusive at the start of therapy.
Exclusion Criteria:
- Present a sensorimotor impairment;
- Have a diagnosis of intellectual disability (intelligence quotient below 75);
- Alcohol or drug abuse;
- A neurological issue (e.g., hemifacial spasms, Huntington's disease);
- Change medication one month or less before step 1 and up to step 4 (last measurement time) without informing a member of the research team;
- Simultaneously receive another intervention for tics (e.g., psychologist, massage therapist) without informing a research team member.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Cognitive-psychophysiological therapy (CoPs).
Six therapeutic steps: 1) Awareness training; 2) Profile of high/low-risk situations for tics; 3) Muscular discrimination; 4) Reduction of sensorimotor activation and modification of action planning style; 5) Cognitive, metacognitive, and behavioral restructuring in high-risk tic situations; 6) Generalization and relapse prevention. The individual sessions last 80 minutes: 55 minutes of therapy, 20 minutes of active listening and 5 minutes for a computer activity. The active listening and activity are unrelated to the analyses but ensure that treatment modalities are equivalent in duration and use of a computer. Participants will be informed about the duration of the therapy (10 to 12 sessions weekly) and that its completion requires continuous attendance at the sessions. The program has been adapted for youth with a treatment guide containing examples and exercises tailored for better understanding. Adolescents aged 14 to 17 will receive this manual to support their comprehension. |
Focus on the processes influencing thoughts and behaviors underlying tics.
|
|
Experimental: Cognitive-psychophysiological therapy (CoPs) combined with biofeedback exercises.
After each 55-minute CoPs session (same protocol as arm 1), 25 minutes will be dedicated to biofeedback exercises (80 minutes total). This 25-minute period includes 2 minutes to record the baseline resting level, 15 minutes for the active biofeedback session, and 2 minutes for the second resting measurement. Active electromyographic (EMG) biofeedback will take the form of computer-generated graphs displayed on a screen at 2 meters (horizontal angle). Changes in muscle activity will cause the movement of a balance with a silvered ball; the graphical feedback of this stimulus is particularly effective in capturing the participant's attention and interactive engagement. The goal is to contract the arm muscle to keep the ball balanced for 5 minutes for each arm, then 5 minutes with both arms (15 minutes). |
Biofeedback refers to visual exercises that help improve movement control.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary outcome
Time Frame: The YGTSS is administered trough the study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months))
|
The Yale Global Tic Severity Scale (YGTSS) provides an assessment of motor and vocal tics based on 5 dimensions: number, frequency, intensity, complexity, and interference.
A subtotal of 50 is used to determine the severity of the tics.
A separate scale assesses impairment, or the overall effect of tic disorders on daily functioning, with another subtotal of 50.
In this study, only the tic severity score out of 50 will be used (comparable to other studies focusing on tics).
|
The YGTSS is administered trough the study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months))
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Conners
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
Psychosocial measures For ADHD symptoms, the Conners 3 (8-18 years) or Conners' Adult ADHD Rating Scales (CAARS)
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
CY-BOCS
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
For OCD symptoms, the Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
STAI
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
For anxiety symptoms, the State-Trait Anxiety Inventory (STAI).
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
Perfectionism Scale
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
The adapted/inadapted Perfectionism Scale
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
Beck Depression Invetory
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
For mood-related symptoms, the Beck Depression Inventory will be used.
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
STOP
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
The Style of Planning Action (STOP)
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
Self-Esteem Inventory
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
The short version of the Self-Esteem Inventory.
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
TS-Quality of Life Scale
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
TS-Quality of Life Scale will also be used.
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
Perdue Pegboard Test
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
The evaluation of fine motor dexterity using the Purdue Pegboard will determine the baseline equivalence between groups and test functional differences after treatment.
The Finger-Tapping Test will be administered to assess speed and motor control.
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
Perceived Stress Scale (PSS-14)
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
We will collect a hair sample to measure the cortisol levels of the participants: a 14-item Perceived Stress Scale (PSS-14) will be administered at the 4 time points of measurement.
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
Finger-Tapping Test
Time Frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
The Finger-Tapping Test will be administered to assess speed and motor control.
|
Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).
|
|
DKEFS CWIT
Time Frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
Participants will be assessed with the 4 sections of the DKEFS CWIT: color naming, word reading, inhibition.
|
Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
|
Brief Cannabis Consumption Questionnaire
Time Frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
To attest the consumption of cannabis.
|
Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SCID-5-RV130
Time Frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
The Structured Clinical Interview for DSM-5 - Research (SCID-5-RV130) will allow for clinical screening of disorders that may present a differential or comorbid diagnosis with PTSD, which could impact treatment engagement or outcomes.
|
Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
|
BASC-3-SRP131
Time Frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
The Behavioral Assessment System, 3rd Edition - Self-Report of Personality (BASC-3-SRP131) will be administered to provide an overall profile of affect and behavior, complementing the SCID-5-RV.
|
Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
|
Bem Sex Role
Time Frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
Sex assigned at birth and gender identity will be assessed using the Bem Sex Role Inventory.
|
Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
|
Wechsler
Time Frame: Only in T1 (pre-test) , up to 4 weeks (first interview).
|
General intelligence will be evaluated through subscales of the Wechsler Intelligence Scale for Children/Adults, depending on the participant's age (WAIS-IV, WISC-V: Vocabulary, Matrices).
|
Only in T1 (pre-test) , up to 4 weeks (first interview).
|
|
BRIEF
Time Frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
Executive functions will also be screened using the Brief Inventory of Executive Function (BRIEF), (version for ages 14-18 years or adults).
|
Only in T1 (pre-test) , up to 4 weeks ( first interview).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Julie Leclerc, Psychology, Université du Québec à Montréal- UQAM
- Study Chair: Marc Lavoie, Psychology, Université TÉLUQ
- Study Chair: Marie-France Marin, Psychology, Université du Québec à Montréal-UQAM
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Pathologic Processes
- Genetic Diseases, Inborn
- Disease
- Neurodegenerative Diseases
- Neurodevelopmental Disorders
- Movement Disorders
- Heredodegenerative Disorders, Nervous System
- Basal Ganglia Diseases
- Tic Disorders
- Syndrome
- Tourette Syndrome
Other Study ID Numbers
Other Study ID Numbers
- PJT-191682
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.